Sotatercept

Unassigned

New Medicines

Pulmonary arterial hypertension (PAH)

Information

New molecular entity
Acceleron
Acceleron

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Selective ligand trap of TGF-beta superfamily that rebalances BMPR-II signaling
PAH is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. It often leads to limited physical activity, heart failure, and reduced life expectancy. The 5-year survival rate for patients with PAH is approximately 57% [1].The prevalence of PAH is estimated at 15-52 per million [2].
Pulmonary arterial hypertension (PAH)
Subcutaneous